Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tulmimetostat · DZR123, CPI-0209

Small molecule · Inhibitor of Enhancer of zeste homolog 2 (EZH2) · developed by Novartis Pharmaceuticals

Phase 1/2 Most advanced trial
NVS Developer

What is Tulmimetostat?

Tulmimetostat is an orally available inhibitor of the histone methyltransferase EZH2, the catalytic subunit of polycomb repressive complex 2, and also acts on EZH1. It blocks methylation of histone H3 at lysine 27, altering gene expression in cancer cells. It is being studied in metastatic hormone-sensitive prostate cancer, in combination with darolutamide or abiraterone.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DZR123, CPI-0209
Drug type
Small molecule
Targets
Enhancer of zeste homolog 2 (EZH2), Enhancer of zeste homolog 1 (EZH1) (secondary target)
Mechanism
Inhibitor of Enhancer of zeste homolog 2 (EZH2)
Pathways
histone H3 lysine 27 methylation, polycomb repressive complex 2 (PRC2) signaling, cancer cell proliferation
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
OUQ4N85Z0B

Conditions studied

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Other drugs acting on EZH2

More from Novartis Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Tulmimetostat

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.